Silver Book Fact

Nerve growth factor (NGF) has been found to be a major mediator of inflammatory and neuropathic pain and provides a new therapeutic target.

Watson J, Allen S, Dawbarn D. Targeting New Growth Factor in Pain: What is the therapeutic potential?. BioDrugs. 2008; 22(6): 349-59. http://www.mendeley.com/catalog/targeting-nerve-growth-factor-pain-therapeutic-potential/

Reference

Title
Targeting New Growth Factor in Pain: What is the therapeutic potential?
Publication
BioDrugs
Publication Date
2008
Authors
Watson J, Allen S, Dawbarn D
Volume & Issue
Volume 22, Issue 6
Pages
349-59
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Pregalbin, an antiepileptic drug, produced around a 32% pain reduction (a significant reduction) at week 16 versus around 20% for placebo, in patients with neuropathic pain due to spinal cord…  
  • Antiepileptic drugs relieve persistent neuropathic pain. One meta-analysis found gabapentin to be associated with moderate benefit (equivalent to 30% pain relief) in close to 1 in 2 patients, and…  
  • Researchers have developed several sub-types of ion channels that allow inflammation and growth factors to trigger persistent pain.  
  • In individuals with persistent low back pain, tanezumab, a humanized anti-nerve growth factor antibody, showed clinical and statistical analgesic efficacy that was superior to placebo and naproxen.  
  • A proteasome inhibitor was found to reduce pain and joint destruction in an animal model of osteoarthritis, suggesting that nontoxic proteasome inhibitors could offer a novel pharmacotherapy option.